Alector to Present at Upcoming Healthcare Conferences

Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced presentations at two upcoming investor conferences.

Rhea-AI Summary

Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced presentations at two upcoming investor conferences. The first is at the Barclays Global Healthcare Conference in Miami, scheduled for March 16, 2022, at 3:20 p.m. ET. The second is the Stifel CNS Days Virtual event on March 28, 2022, at 11:30 a.m. ET. Both presentations will be available via live webcasts, with replays accessible for 90 days on Alector's website. Alector aims to treat neurodegenerative diseases by addressing immune dysfunction.

Argus Session date unavailable

+12.45% session move Open Argus

Details

News Market Reaction – ALEC

The recorded move for ALEC in the trading session of this news was +12.45%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will present at the following upcoming investor conferences:

• Barclays Global Healthcare Conference (Miami, Florida)
  • Wednesday, March 16, 2022 at 3:20 p.m. ET, Fireside Chat
• Stifel CNS Days (Virtual)
  • Monday, March 28, 2022 at 11:30 a.m. ET, Corporate Presentation

Live webcasts of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Contacts:

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com

Argot Partners (investors)
Eric Kasper/Carrie McKim
Argot Partners
212.600.1902
alector@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Alector's presentation at the Barclays Global Healthcare Conference?

Alector will present on March 16, 2022, at 3:20 p.m. ET.

What is the date of Alector's presentation at Stifel CNS Days?

Alector's corporate presentation at Stifel CNS Days is scheduled for March 28, 2022, at 11:30 a.m. ET.

Where can I watch Alector's investor conference presentations?

You can watch Alector's presentations live on their 'Events & Presentations' page on their website.

How long will Alector's webcast replays be available?

Replays of Alector's webcasts will be available for 90 days after the presentation dates.

What is the focus of Alector's research?

Alector focuses on immuno-neurology, targeting immune dysfunction to treat neurodegenerative diseases like Alzheimer's and frontotemporal dementia.